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Summary The aim of the present retrospective study was to assess long-term survival after cisplatin-based
chemotherapy in 398 patients with advanced urothelial transitional cell carcinoma (TCC) treated at seven
international oncological units. Various combinations ofcisplatin, methotrexate, vinblastine (or vincristine) and
doxorubicin were used. The complete response rate according to the WHO criteria was 17%. Partial responses
were obtained in 42% of the patients. The overall cancer-related 2 year and 5 year survival rates were 21% and
11% respectively. Based on multivariate analyses, a good prognosis group could be identified comprising
patients with a good performance status with disease confined to lymph nodes (14%) or patients with T4b
disease only. These patients had a 28% 5 year survival rate, which, in part, has to be related to post-
chemotherapy consolidation treatment in patients with pelvis-confined disease (radiotherapy, 26%; total
cystectomy, 11%). Fifteen patients died of chemotherapy-related complications and in 16% of the patients
toxicity led to discontinuation of treatment. Modern cisplatin-based chemotherapy leads to long-term survival
and cure of selected patients with advanced urothelial transitional cancer. In routine clinical practice,
chemotherapy should be offered to good prognosis patients; those presenting with a good performance status
and a non-metastasising T4b tumour or with metastases confined to lymph nodes. Post-chemotherapy
consolidation treatment by surgery or radiotherapy should always be considered. Such chemotherapy requires
oncological expertise in order to avoid unnecessary toxicity.
Keywords: bladder cancer; metastasis; chemotherapy
In the United States bladder cancer is the fifth most common
cancer in men and the seventh in women, with an annual
incidence of approximately 18 cases per 100 000 or more than
52 900 new cases per year, leading to 11 700 deaths annually
(American Cancer Society, 1996). The annual age-adjusted
incidence in the Nordic countries is about 35 cases per
100 000, and the mortality 12 per 100 000 (Engeland et al.,
1993, 1995). Bladder cancer is primarily a disease of the
elderly, with 80% of cases in the 50-79 year age group, and
a peak incidence in the seventh decade. About 20-30% of all
patients present with advanced bladder cancer [extension to
the pelvic wall (T4b); metastatic disease (N+, M+)], while
about 50% of all patients with muscle-invasive bladder
cancer develop a pelvic recurrence or metastases during the
course of their disease, despite curatively intended surgery or
radiotherapy.
Systemic chemotherapy has an uncertain role in the
treatment of locally advanced recurrent metastatic urothelial
transitional cell carcinoma (TCC). Anti-tumour activity has
been demonstrated with several single agents, but does not
prolong survival. Cisplatin-based combination chemotherapy
leads to response rates between 35% and 70% and is more
effective than cisplatin alone (Sternberg et al., 1989; Harker et
al., 1985; Foss'a et al., 1982; Loehrer et al., 1992). Typically,
the response rates from single institution studies are superior
to those from multicentre trials. Prolonged survival has been
reported in patients who achieve complete response (CR)
(Logothetis et al., 1985; Stoter et al., 1987; Sternberg et al.,
1989). Systemic cisplatin-based combination chemotherapy
can be toxic, particularly in elderly patients. The potential
toxicity must, therefore, be balanced against the expected
beneficial effects, such as palliation of pain and, in particular,
increase in life expectancy.
The aim of the present paper is to analyse the survival in
patients with advanced urothelial cancer of pure TCC type
treated with cisplatin-based combination chemotherapy at six
European centres (NRH, Norwegian Radium Hospital; IGR,
Institute Gustave Roussy; RMH, Royal Marsden Hospital;
NCCT, Northern Centre for Cancer Treatment; RSHH,
Royal South Hants Hospital; HSR, San Raffaele Scientific
Institute) and at one American hospital (MSKCC, Memorial
Sloan Kettering Cancer Center). In addition, we examined
which prognostic factors may assist the clinician in selecting
those patients in whom long-term survival can be expected.
Patients and methods
The above six European and one American hospitals
contributed the clinical data from 398 patients to this study
(Table I). Patients with brain metastases at presentation were
excluded. All patients had measurable locally advanced or
metastatic urothelial cancer arising from the bladder, ureter
or the renal pelvis. All patients had pure TCC. None of the
patients had received chemotherapy before the study
treatment. Fifty-three patients had T4b bladder cancer
without prior treatment. Sixty-three patients had undergone
total cystectomy before systemic chemotherapy. A further 79
patients had been treated with pelvic radiotherapy with or
without bladder-conserving surgery (TUR B; bladder wall
resection). Pulmonary metastases were the only site of
metastatic disease in 43 patients. Forty-nine patients had
disease confined to lymph node sites. About two-thirds of the
patients had a good performance status [WHO grade 0 or 1
(Miller et al., 1981)] at the start of chemotherapy.
The European hospitals used a variety ofcisplatin-contain-
ingcombination chemotherapy regimens with cisplatin doses of
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70-100 mg m- per cycle, administered every third week.
These included CMV, cisplatin, methotrexate, vinblastine
(Harker et al., 1985); CMO, cisplatin, methotrexate, vincris-
tine; CM, cisplatin, methotrexate. Patients received between
one and seven cycles of chemotherapy (median, three cycles)
(Table II). At the MSKCC and in Rome, only M-VAC
[methotrexate, vinblastine, doxorubicin, cisplatin (Sternberg et
al., 1988)] was used. In the patients treated at the MSKCC the
median number ofcycles was four (range 1 -8).
In the present report, response was defined according to the
WHO criteria (Miller et al., 1981). Complete remission, CR;
partial remission, PR; no change, NC; progression, PD. In 34
patients total cystectomy could be performed after cisplatin-
based chemotherapy. Post-chemotherapy radiotherapy was
used in 88 patients. In particular, ofthe 245 patients with T4b
disease or metastases confined to the pelvic lymph nodes, 28
(11%) and 64 (26%) underwent post-chemotherapy, total
cystectomy and radiotherapy respectively. Forty-three patients
received second-line alternative chemotherapy after failure of
the initial chemotherapy regimen. A total of 109 patients were
not given any further anti-cancer treatment after discontinua-
tion ofcisplatin-based chemotherapy.
Statistics
A biostatistician (ES) performed procedures and tests using
SPSS version 6.1 for PC. The primary outcome variable was
the cancer-related actuarial survival from the start of
chemotherapy, evaluated by Kaplan-Meier estimates and
the log-rank test. Cancer-related death was defined as death
from or with urothelial cancer, including death during
chemotherapy owing to complications from chemotherapy.
A multivariable survival analysis was performed by the Cox
proportional hazards model. Proportionality assumptions
were checked and confirmed for the variables included. A
P-value <0.05 was regarded as statistically significant.
Results
At the end of the observation period (December 1994) and
with a median follow-up of 51 months (range, 3-158
months) 48 patients were alive and 350 were dead. Twelve
of the surviving patients were alive with disease and 36
patients were without evidence of urothelial cancer. Seven
patients have died as a result of intercurrent diseases without
evidence of urothelial cancer. In 343 patients death was
cancer-related. In 53 of 340 evaluable patients (16%),
chemotherapy-induced toxicity led to discontinuation of
treatment. Complications of chemotherapy were the cause
of death in 15 (4%) of these patients. Three cancer-related
deaths occurred more than 5 years after the initiation of
chemotherapy. The cancer-related 2 year and 5 year survival
rates were 21% and 11%, respectively, for all patients, with a
median survival time of 11.3 months (Figure 1).
Response was assessed in 336 patients (Table III).
Complete response was achieved in 17% [95% confidence
interval (CI) 13-21%] and partial response in 42% (95% CI
37-47%). In patients with lymph node metastases as their
only site of disease, a 47% CR rate was reported (95% CI
31-63%). Patients achieving a CR had a 38% 5 year survival
rate (Figure 2).
In the univariable analysis (Table IV) the median survival
ofpatients with T4b tumours and those with disease confined
either to lymph nodes or lung metastases was superior to that
of patients with other or multiple sites of advanced disease.
The 5 year survival rates were: patients with lymphatic
metastases only, 18%; patients with T4b tumours, 25%;
patients with lung metastases only, 11%; patients with
combined or alternative metastatic sites, 7% (Figure 3).
Patients with a history of prior radiotherapy had a decreased
survival compared with non-irradiated ones. Patients who
had received M-VAC chemotherapy had a better outcome
than those treated with non-M-VAC chemotherapy.
The following pretreatment parameters were included in a
multivariable analysis: performance status, site of disease (T4
or lymph node metastases only vs all other alternatives) and
age. Haemoglobin was excluded from this analysis as this
factor may vary according to blood transfusion policy. The
following independent good prognosis factors were con-
Table I Patient characteristics
No. of patients
Norwegian Radium Hospital, Oslo
Institute Gustave Roussy, Villejuif
Northern Centre for Cancer Treatment,
Newcastle
Royal Marsden Hospital, London
Royal South Hants Hospital, Southampton
San Raffaele Scientific Institute, Rome
Memorial Sloan Kettering Cancer Center,
New York
Males/females
Mean age at chemotherapy (years)
Performance status (WHO)
0
1
2
3
4
Unknown
Disease manifestation
T4b bladder cancer only
Lymph node metastases onlyb
Lung metastases only
Biochemistry
Mean haemoglobin (gdl-1)c
Previous treatment
None or bladder-conserving surgeryd
(without radiotherapy)
Cystectomy
Pelvic irradiation (with or without
bladder-conserving surgeryd)
Other
Unknown
398
76
54
33
53
53
27
102
326/72
62 (23-80)a
93
176
86
27
3
13
53
492
12.3
(5.6- 18.0)
202
63
79
39
15
aRange. bPelvic, 27; extrapelvic, 22. CMissing for 41 patients.
dIncludes TUR B and partial cystectomy.
Table II Chemotherapy
Cisplatin monotherapy 3
CMV 83
M-VAC 188
CMO 30
CM 46
Other 48
C, cisplatin; M, methotrexate; V, vinblastine; A, doxorubicin
(adriamycin); 0, vincristine (oncovin).
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Figure 1 Cancer-related survival for all 398 patients.
--
v.v 7firmed: performance status 0/1; T4 or lymph node metastases
only and age <65 years. Combining the first two factors, a
good prognosis group could be defined consisting of patients
with a good performance status without visceral metastases.
These patients represented about 20% of the patients from
the present series (81 patients) and displayed a 5 year cancer-
related survival of 28% with a median survival rate of 20
months (compared with 10 months in patients from the poor
prognosis group) (Figure 4).
In Table VI the proportion of good prognosis patients
(performance status 0/1 and no visceral metastases) is given
for each of the contributing institutions, showing a variability
from 9-55%.
Discussion
In the last decade clinicians have become increasingly aware
that TCC of the urothelial tract is responsive to combination
chemotherapy. As TCC represents the vast majority of
urothelial cancer seen in routine clinical practice, and for the
sake ofhomogeneity, we have performed the present analysis in
pure TCC only. The most commonly used regimens are the
CMV (Harker et al., 1985) and the M-VAC combination
(Sternberg et al., 1988). M-VAC has been shown to be superior
to single-agent cisplatin (Loehrer et al., 1992) and to CISCA
(Logothetis et al., 1990) in randomised trials. No randomised
trial has been performed comparing M-VAC and CMV.
Table III Sites of disease and response rates
No ofassessed patients No
Site Total CRa PR" response
Lung metastases only 28 4 (14%) 14 (50%) 10
Lymph node 38 18 (47%) 11 (29%) 9
metastases only
T4b tumour only 46 10 (28%) 16 (35%) 20
Other metastatic 224 25 (11%) 100 (45%) 99
sites/combinations
Total 336 57 (17%) 141 (42%) 138
aComplete response. bPartial response.
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Response rates of 35-70% are reported in patients
receiving M-VAC or CMV, with CR rates of 13-20%.
These figures are confirmed in the present study. In the
literature the median duration of response is reported to be
about 9 months. As has been shown by other authors in
single-institution studies, cisplatin-based chemotherapy is
more effective in patients with nodal disease as compared
with visceral disease [response rates, 71% vs 40%; survival,
33 months vs 12 months (Logothetis et al., 1985; Sternberg et
al., 1989)]. In patients with visceral metastases, pulmonary
lesions display the highest response rates, whereas hepatic
and skeletal deposits are reported to be less responsive.
Cisplatin-based chemotherapy of urothelial cancer repre-
sents a potentially curative treatment which, however, may be
severely toxic in these often elderly patients who frequently
present with concomitant medical problems and chronic
diseases (Tannock et al., 1989; Foss'a et al., 1992). In
addition, owing to advanced age and the malignancy, renal
1.0 -
0.8 -
-
U. _0.6-
2 0.4-
n
0.2 - PR
<C /P
<CR/P ___.____
24 36 48 60 72 84 96
Months since chemotherapy start
0 12
l
108 120
Figure 2 Cancer-related survival according to response to
cisplatin-based chemotherapy. CR, complete response (57
patients); PR, partial response (141 patients); <CR/PR, no
response (138 patients).
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cn Table IV Univariable analysis of pretreatment variables
Median cancer-related
Variable survival months P-value
Sites of disease
T4 only 13.4
Lymph nodes only 15.0
Lung only 15.8
Other combination 9.8 <0.0001
Haemoglobin (gdl-')
> 12.0 12.3
< 12.0 8.3 <0.0001
Chemotherapy
M-VAC 13.0
Non-M-VAC 9.0 <0.0001
Gender
Males 11.5
Females 10.8 0.37
Age (years)
<65 12.0
>65 years 9.8 0.01
Performance status
0/1 12.4
2-4 8.1 0.01
Previous radiotherapy
Yes 6.2
No/Unknown 12.0 <0.0001
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Figure 3 Cancer-related survival according to site of disease. 1,
T4 only (53 patients); 2, metastases confined to lymph nodes (49
patients); 3, lung metastases only (34 patients); 4, other sites or
> 1 site (262 patients).
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Figure 4 Cancer-related survival in the good prognosis group.
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Table V Multivariable analysis of pretreatment variables
Estimated hazard ratio
(95% confidence
Variable interval) P-value
Performance status 0.51 (0.40-0.65) <0.0001
0/1 vs 2-4
Site of disease manifestation 0.53 (0.40-0.70) <0.0001
(T4b or lymph nodes
only vs lung/others)
Age (years)
(>65 vs<65) 1.32 (1.06-1.65) 0.01
Table VI Proportion of good prognosis patients treated at each
hospital
Good risk group
Hospital Total (no. ofpatients)
NRH 75a 27 36%
IGR 54 9 17%
RMH 53 5 9%
NCCT 33 18 55%
RSHH 53 5 9%
MSKCC 102 11 11%
HSR 27 6 22%
Total 397 81 20%
aInsufficient data for one patient. For abbreviations, see text.
function is often reduced and commonly below the level
required for cisplatin administration (glomerular filtration
rate >50 ml min-'). The application of careful hydration,
modern antiemetics, the use of leucovorin (to prevent
mucositis) and/or haematological growth factors (Grabri-
love et al., 1988) can reduce toxicity. Other cisplatin-based
combination regimens have been introduced in the last
decade in an attempt to reduce toxicity. This is also the
background for the use of vincristine instead of vinblastine,
or the substitution of epirubicin or mitosantrone for
doxorubicin, or of carboplatin for cisplatin (St6ckle et al.,
1992; Waxman et al., 1989; Boccardo et al., 1994). Severe
toxicity may, however, occur even among these carefully
selected patients. Four per cent of our 398 patients died as a
result of chemotherapy-related toxicity. Furthermore, 34 of
292 evaluable patients (12%) received only one course of
chemotherapy. Chemotherapy was discontinued owing to
toxicity in 31 patients, to deterioration of the general
condition in 14 or to patient refusal in 8. These figures are
in accordance with published information on toxicity, and
underline the need for careful consideration of the aims of
therapy when initiating this type of chemotherapy in an
individual patient.
Nevertheless, there are clearly beneficial effects of
cisplatin-based chemotherapy in patients with advanced
urothelial cancer. Although the 5 year survival rate was
only 11%, patients with a good performance status and with
disease confined to lymph nodes only or unresectable T4b
bladder cancer may achieve long-term survival (>3 years)
with a 28% 5 year survival rate. Inoperable patients may
become operable following chemotherapy, as occurred in the
31 patients who were able to undergo post-chemotherapy
cystectomy. As radiotherapy is usually most effective in small
tumours, preirradiation chemotherapy leading to tumour size
reduction may increase the chance of radiocurability of a
tumour in subgroups of patients. Our series thus supports the
view that selected patients with technically inoperable pelvis-
confined tumours may benefit from consolidation treatment
with surgery or radiotherapy after maximum response to
chemotherapy (Dimopoulos et al., 1994; Miller et al., 1993).
Other authors have reported the significance of prognostic
factors during chemotherapy of urothelial cancer (Geller et
al., 1991; Sengel0v et al., 1994). At the MSKCC, favourable
prognostic factors for survival in patients treated with M-
VAC included a good performance status, age >60 years,
and a normal serum alkaline phosphatase. Sengel0w et al.
(1994) confirmed the importance of a good performance
status and of a normal alkaline phosphatase for long-term
survival, and added normal serum creatinine to the list of
good prognostic factors. In the Intergroup study, which
compared M-VAC with cisplatin, the most important
prognostic factors for favourable outcome were a good
performance status, weight loss of <10%, and lack of
visceral metastases (Loehrer et al., 1992). Patients who had
all three favourable factors had a 64% response and a
median survival of 18 months. The present study confirms the
favourable effect of good prognosis factors, such as a good
performance status and lack of visceral metastases, as
predictive parameters of long-term survival. Contrary to the
report by Geller et al. (1991), younger patients from the
present series had a better outcome than older ones. As
reported by Stoter et al. (1987) and by Logothetis et al.
(1985), patients with CR had the best survival, whereas PR
was not related to a beneficial long-term survival. Jeffery and
Mead (1992) suggested that patients with advanced ureteric
or renal pelvis TCC represented a good prognostic group.
Owing to lack of relevant information this factor could not
be analysed in this study.
The present study highlights the variability of selection
factors for patients treated for advanced urothelial cancer at
different oncological institutions. The heterogeneous distribu-
tion of prognostic factors among patients from different
institutions may explain the variability of response rates
recorded in the literature, and the need to stratify results
according to prognostic factors.
In conclusion, cisplatin-based chemotherapy is both
feasible and efficacious in carefully selected patients with
advanced urothelial cancer. The overall response rate is 59%
(CR, 17%; PR, 42%) and the 5 year cancer-related survival is
11%. Post-chemotherapy surgery or radiotherapy should
always be considered. There is the need for improved
chemotherapy regimens and, in particular, for the identifica-
tion of new effective drugs and drug combinations, including
ifosfamide (Witte et al., 1993) and paclitaxel (Roth, 1995).
Patients with a good performance status and with disease
confined to lymph nodes or with a T4b bladder cancer as
their only disease site have a 28% 5 year survival rate.
Cisplatin-based chemotherapy in patients with advanced
urothelial cancer requires oncological expertise in order to
obtain optimal results and to avoid unnecessary toxicity.
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